Health Economics›Breast cancer›Metastatic disease first-line chemotherapy

Metastatic disease first-line chemotherapy

Breast cancer · 41 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 30 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Paclitaxel, nanoparticle albumin-bound and Bevacizumab Variant #01	—	R 102 337	28d	9.3 mo	—	2	R 204 675 PFS proxy	2
Capecitabine and Paclitaxel, nanoparticle albumin-bound Variant #01	—	R 41 026	21d	—	—	~2	~R 82 052 indirect	—
Paclitaxel and Bevacizumab Variant #01	—	R 40 612	28d	11.0 mo	28.5 mo	2	R 81 225 PFS proxy	6
Docetaxel and Bevacizumab Variant #01	—	R 32 908	21d	9.7 mo	—	9	R 296 169 PFS proxy	2
FEC and Bevacizumab Variant #01	—	R 32 496	21d	9.2 mo	—	8	R 259 971 PFS proxy	1
Cyclophosphamide and Epirubicin (EC) and Bevacizumab Variant #01	—	R 32 416	21d	9.2 mo	—	8	R 259 324 PFS proxy	1
Capecitabine and Bevacizumab Variant #01	—	R 31 025	21d	8.7 mo	26.1 mo	2	R 62 050 PFS proxy	2
FAC and Bevacizumab Variant #01	—	R 30 700	21d	9.2 mo	—	8	R 245 596 PFS proxy	1
Cyclophosphamide and Doxorubicin (AC) and Bevacizumab Variant #01	—	R 30 619	21d	9.2 mo	—	8	R 244 949 PFS proxy	1
nab-Paclitaxel monotherapy Variant #01	—	R 16 043	28d	6.9 mo	18.7 mo	2	R 32 087 PFS proxy	5
Pemetrexed monotherapy Variant #01	—	R 13 225	21d	~3.0 mo	~9.0 mo	~9	~R 119 025 PFS proxy · indirect	21
Pegylated liposomal doxorubicin monotherapy Variant #02	—	R 8 000	28d	6.3 mo	—	2	R 16 000 PFS proxy	2
Docetaxel and Gemcitabine Variant #01	—	R 6 266	21d	—	26.9 mo	9	R 56 391 PFS proxy	2
Gemcitabine and Paclitaxel Variant #01	—	R 5 224	21d	6.5 mo	18.6 mo	6	R 31 344 PFS proxy	2
Docetaxel and Epirubicin (DE) Variant #01	—	R 4 064	21d	—	—	~6	~R 24 386 indirect	—
Capecitabine and Docetaxel (TX) Variant #01	—	R 3 311	21d	8.4 mo	—	4	R 13 243 PFS proxy	1
Epirubicin monotherapy Variant #01	—	R 3 200	21d	8.2 mo	19.1 mo	7	R 22 400 PFS proxy	—
Epirubicin and Vinorelbine (VE) Variant #01	—	R 3 091	21d	10.1 mo	—	18	R 38 231 PFS proxy	—
Docetaxel monotherapy Variant #02	—	R 2 921	28d	8.2 mo	32.6 mo	6	R 17 529 PFS proxy	5
Docetaxel monotherapy Variant #02	ERBB2	R 2 921	28d	8.2 mo	32.6 mo	6	R 17 529 PFS proxy	5
Docetaxel and Doxorubicin (AT) Variant #01	—	R 2 779	21d	—	22.0 mo	8	R 20 207 PFS proxy	1
Epirubicin and Paclitaxel (EP) Variant #01	—	R 2 715	21d	10.8 mo	22.4 mo	4	R 10 860 PFS proxy	1
Cyclophosphamide and Epirubicin (EC) Variant #01	ERBB2	R 2 429	21d	8.0 mo	20.3 mo	8	R 19 434 PFS proxy	1
Cyclophosphamide and Epirubicin (EC) Variant #01	—	R 2 429	21d	8.0 mo	20.3 mo	8	R 19 434 PFS proxy	1
Capecitabine and Paclitaxel Variant #01	—	R 2 081	21d	—	—	~2	~R 4 162 indirect	—
FEC Variant #01	—	R 2 049	21d	8.0 mo	19.2 mo	2	R 4 097 PFS proxy	1
Paclitaxel and Vinorelbine Variant #01	—	R 1 936	28d	—	—	~2	~R 3 872 indirect	—
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	~4.6 mo	~11.0 mo	~7	~R 11 705 PFS proxy · indirect	16
Doxorubicin and Paclitaxel (AT) Variant #01	—	R 1 609	21d	—	25.3 mo	9	R 13 972 PFS proxy	1
FAC Variant #11	—	R 1 076	21d	8.0 mo	17.3 mo	9	R 9 685 PFS proxy	3
Capecitabine monotherapy Variant #01	—	R 1 039	21d	6.0 mo	—	8	R 8 309 PFS proxy	4
Capecitabine monotherapy Variant #01	ERBB2	R 1 039	21d	6.0 mo	—	8	R 8 309 PFS proxy	4
CMFT Variant #01	—	R 910	28d	—	—	~2	~R 1 819 indirect	—
Doxorubicin monotherapy Variant #01	—	R 902	21d	7.7 mo	13.8 mo	9	R 8 114 PFS proxy	1
Cyclophosphamide and Doxorubicin (AC) Variant #01	—	R 864	21d	8.0 mo	20.3 mo	6	R 5 185 PFS proxy	1
Cyclophosphamide and Doxorubicin (AC) Variant #01	ERBB2	R 864	21d	8.0 mo	20.3 mo	6	R 5 185 PFS proxy	1
Paclitaxel monotherapy Variant #02	—	R 734	28d	6.9 mo	20.5 mo	7	R 5 141 PFS proxy	16
Paclitaxel monotherapy Variant #02	ERBB2	R 734	28d	6.9 mo	20.5 mo	7	R 5 141 PFS proxy	16
CMF Variant #01	—	R 291	28d	—	21.5 mo	2	R 582 PFS proxy	—
Cyclophosphamide and Non-pegylated liposomal doxorubicin (MC) Variant #01 Partial	—	R 150	21d	—	—	~2	~R 301 indirect	—
S-1 monotherapy Variant #01 Partial	—	—	21d	—	32.6 mo	2	—	2

41 of 41 regimens shown